Platelet-to-lymphocyte ratio for prognostication in immune checkpoint inhibitor-treated cancer patients - a meta-analysis of 13027 patients highlighting nivolumab-responsive renal cell carcinoma
Favorite
Share
More Options
22

Open in WPS to view all 22 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
